SpecificationOrganism/cell\
line/tissue*Homo Sapiens, tissue*Sex*Male and Female*Sequencer or array type*NanoString nCounter assay*Data format*Raw data: .txt, Normalized data: SOFT, MINiML, Series Matrix*\
*(.txt)*Experimental factors*Gene expression in tissue*Experimental features*Gene expression profiles were obtained by using total RNA extracted from formalin-fixed paraffin-embedded liver biopsy tissue specimens.*Consent*Requirement of consent was waived on condition that all patients be made anonymous*Sample source location*Mass General Hospital, Boston MA, U.S., 42.3628° N, 71.0686° W*

Direct link to deposited data {#s0040}
=============================

Deposited data can be found here: <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE54100>.

Experimental design, materials and methods {#s0005}
==========================================

Tissue samples {#s0010}
--------------

All of the patient samples were collected from liver biopsies performed at Massachusetts General Hospital. All patients had a histological diagnosis of cirrhosis and had confirmed HCV infection based on positivity of serum HCV antibody or RNA.

RNA preparation {#s0015}
---------------

Total RNA was prepared from 10 μm-thick formalin-fixed paraffin-embedded (FFPE) tissue sections by using a High Pure RNA Paraffin kit (Roche) according to the manufacturer\'s instructions. RNA quality was assessed by qRT-PCR of a housekeeping gene RPL13A as previously described [@bb0005]. All samples were confirmed to have a crossover threshold (Ct) value less than 33 and an RNA concentration greater than 20 ng/μl, and 100 to 500 ng total RNA was subjected to the expression profiling.

NanoString nCounter assay and data normalization {#s0020}
------------------------------------------------

The 186-gene signature defined and validated in our previous studies [@bb0005], [@bb0015] was implemented in the nCounter digital transcript counting assay specifically designed for the analysis of clinical specimen including archived FFPE tissue (GEO accession number GPL17230) [@bb0025], [@bb0030], [@bb0040], [@bb0045], [@bb0050]. The assay was run according to the manufacturer\'s instruction on a high sensitivity "green" New Prep Plate, and hybridized cartridges were scanned using an nCounter Digital Analyzer. Raw transcript count data were log-transformed (base 2) and scaled by geometric mean of control probe data (annotated as "normalization_gene") by using the NanoString normalizer module implemented in the GenePattern genomic analysis toolkit ([www.broadinstitute.org/genepattern](http://www.broadinstitute.org/genepattern){#ir0020}). A floor value of 1.1 was applied before the log-transformation.

Bioinformatics data analysis {#s0025}
----------------------------

The 186-gene signature-based outcome prediction was performed using the nearest template prediction algorithm implemented in the GenePattern Nearest Template Prediction module [@bb0060] and the prediction model reported in our initial publication without making any modification [@bb0005]. The prognostic association of the gene signature-based prediction was evaluated by the Kaplan--Meier curves, log-rank test, and Cox regression modeling.
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